What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Lung cancer, Internal medicine, Oncology, Surgery and Carcinoma.
His Lung cancer study combines topics from a wide range of disciplines, such as Positron emission tomography, Radiology, Nuclear medicine, Stage and Survival analysis.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Placebo.
His study in Oncology is interdisciplinary in nature, drawing from both KRAS, Disease, Evidence-based medicine, Docetaxel and Gemcitabine.
The study incorporates disciplines such as Clinical trial and Anemia in addition to Surgery.
The various areas that Johan Vansteenkiste examines in his Clinical trial study include Atypical adenomatous hyperplasia, Tolerability and Predictive marker.
His most cited work include:
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2655 citations)
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer (2559 citations)
What are the main themes of his work throughout his whole career to date?
Johan Vansteenkiste mainly focuses on Internal medicine, Oncology, Lung cancer, Surgery and Chemotherapy.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
In his research, Atezolizumab is intimately related to Docetaxel, which falls under the overarching field of Oncology.
His Lung cancer study integrates concerns from other disciplines, such as Stage, Clinical trial, Radiology and Carcinoma.
Johan Vansteenkiste has included themes like Metastasis and Lymph node in his Radiology study.
His Surgery study deals with Placebo intersecting with Hazard ratio.
He most often published in these fields:
- Internal medicine (56.12%)
- Oncology (44.39%)
- Lung cancer (40.82%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (56.12%)
- Oncology (44.39%)
- Lung cancer (40.82%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Lung cancer, In patient and Cancer research are his primary areas of study.
His study in Osimertinib, Chemotherapy, Durvalumab, Docetaxel and Chemoradiotherapy is carried out as part of his studies in Internal medicine.
His Oncology research is multidisciplinary, relying on both Nivolumab, Atezolizumab and Clinical trial.
Johan Vansteenkiste has researched Lung cancer in several fields, including Carcinoma, Radiology and Immunotherapy.
His work investigates the relationship between Radiology and topics such as Randomized controlled trial that intersect with problems in Stage.
His Cancer research research includes elements of KRAS, Capmatinib and Kinase.
Between 2016 and 2021, his most popular works were:
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (1436 citations)
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (912 citations)
- Phenotype molding of stromal cells in the lung tumor microenvironment. (402 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Osimertinib and Cancer research.
Johan Vansteenkiste works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Confidence interval, as a part of the same area of interest.
His Oncology research is multidisciplinary, incorporating perspectives in Stage and Immunohistochemistry, Clinical trial, Pathology.
His Lung cancer study incorporates themes from Carcinoma and Docetaxel.
Johan Vansteenkiste focuses mostly in the field of Osimertinib, narrowing it down to matters related to T790M and, in some cases, EGFR T790M, Discontinuation, Erlotinib Hydrochloride, Dacomitinib and Survival rate.
His work on Stromal cell as part of general Cancer research research is frequently linked to Profiling, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
